Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease

Graeme K Ambler, Joakim Nordanstig, Christian-Alexander Behrendt, Chris P Twine*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

4 Downloads (Pure)

Abstract

The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial showed that aspirin, in combination with low dose rivaroxaban, significantly reduced cardiovascular events compared with aspirin alone for the subgroup of patients with symptomatic lower extremity arterial disease (LEAD). Some of this benefit was mitigated by increased major bleeding events in the aspirin with rivaroxaban arm. 1 Twenty-one years before COMPASS, the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) randomised trial showed that clopidogrel also significantly reduced cardiovascular events over aspirin without increasing major bleeding in a similar cohort. No other antithrombotic regimen has ever been shown to have a significant net clinical benefit over aspirin for patients with symptomatic LEAD.
Original languageEnglish
Pages (from-to)654-655
JournalEuropean Journal of Vascular and Endovascular Surgery
Volume62
Issue number4
Early online date24 Aug 2021
DOIs
Publication statusPublished - 1 Oct 2021

Keywords

  • Lower extremity arterial disease
  • Drug therapy
  • Platelet aggregation inhibitors
  • Randomised controlled trial
  • Secondary prevention

Fingerprint

Dive into the research topics of 'Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease'. Together they form a unique fingerprint.

Cite this